How important could be a loss of coordination roles in EU collaborations be and how could this affect sciences revenues?
With the European Medicines Agency forced to leave London in an out-vote, what extent will Britain’s role in regulating medicine be diminished?
In what ways could Brexit threaten inward investment into UK life sciences? Could restoring full sovereignty enable the UK to re-strategise and become more pro-science?
How should life science companies be preparing for the exit?
